CTOs on the Move

Kedrion

www.kedrion.com

 
Kedrion Biopharma develops and produces plasma-derived therapies, making them available to meet patients` needs the world over. We collect and fractionate blood plasma for the development, production and distribution of plasma derivatives used in the treatment of patients suffering from rare and chronic conditions such as hemophilia and immune system deficiencies. A corporation is not a person, but a corporation is run by people and it affects people. And Kedrion`s business is people. The very nature of our enterprise is to help people live more full and healthy lives. This commitment extends to how we conduct our business, that is, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.kedrion.com
  • 400 Kelby St Fl 11
    Fort Lee, NJ USA 07024
  • Phone: 201.242.8900

Executives

Name Title Contact Details

Similar Companies

Somanetics Corporation

Somanetics Corporation is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Myers Group

The Myers Group is a Duluth, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Transcarent

Transcarent is a new consumer-directed health and care platform for employees of self-insured employers and their families. Using a combination of software, technology, Health Guides and data science, Transcarent empowers consumers with unbiased information, trusted guidance and access to high-value care.

Ampio Pharmaceuticals

Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates.  These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending.  Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™.  The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee.  Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema.  Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.

Cedar

Cedar provides a smarter way for hospitals, health systems and medical groups to manage the patient payment ecosystem. Our platform delivers modern intelligence to alleviate collections challenges, dramatically improve billing operations and ensure a personalized billing experience for patients. Most revenue cycle solutions today look at only one or two transactional aspects of patient payments. We believe that the focus instead should be on improving the overall experience of patient billing and engagement. Together with the leading medical groups and hospitals across the country, we are elevating the patient payment experience.